Payment overview · 2025
General Payments
$278.26
13 reported records · 8 companies
Healthcare provider profile · identity verified
Chevone R Vent, MD
Allopathic & Osteopathic Physicians|Family Medicine · UPPER SANDUSKY, OH · NPI 1053578757
Verified facts
What the public records show
CMS Open Payments records show Chevone R Vent, MD received $278.26 in general payments during 2025 across 13 reported records.
Merck Sharp & Dohme LLC accounted for 27.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $76.71 | 27.6% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $39.40 | 14.2% | 2 | 2025 |
| Incyte Corporation | Unresolved — no canonical attribution shown | $37.00 | 13.3% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $30.56 | 11.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $29.70 | 10.7% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $26.15 | 9.4% | 1 | 2025 |
| Exelixis Inc. | Unresolved — no canonical attribution shown | $24.44 | 8.8% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.30 | 5.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $278.26 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $39.40 | 2 | 2025 |
Source payment records
|
|||||
| JAKAFI Normalized: jakafi |
Drug | Incyte Corporation | $37.00 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $30.56 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $29.70 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $26.15 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $25.82 | 1 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $25.82 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $25.82 | 1 | 2025 |
Source payment records
|
|||||
| CABOMETYX Normalized: cabometyx |
Drug | Exelixis Inc. | $24.44 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $23.40 | 1 | 2025 |
Source payment records
|
|||||
| KEYTRUDA Normalized: keytruda |
Biological | Merck Sharp & Dohme LLC | $22.27 | 1 | 2025 |
Source payment records
|
|||||
| KEYTRUDA QLEX Normalized: keytruda qlex |
Biological | Merck Sharp & Dohme LLC | $22.27 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $16.00 | 1 | 2025 |
Source payment records
|
|||||
| PENBRAYA Normalized: penbraya |
Biological | PFIZER INC. | $16.00 | 1 | 2025 |
Source payment records
|
|||||
| TRUMENBA Normalized: trumenba |
Biological | PFIZER INC. | $16.00 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $14.95 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $14.30 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
60 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
43 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 490 | 133 |
| Amlodipine Besylate | Amlodipine Besylate | 287 | 81 |
| Levothyroxine Sodium | Levothyroxine Sodium | 278 | 69 |
| Omeprazole | Omeprazole | 278 | 65 |
| Lisinopril | Lisinopril | 277 | 71 |
| Glimepiride | Glimepiride | 239 | 58 |
| Simvastatin | Simvastatin | 223 | 51 |
| Metformin Hcl | Metformin Hcl | 216 | 54 |
| Furosemide | Furosemide | 208 | 69 |
| Potassium Chloride | Potassium Chloride | 202 | 64 |
| Losartan Potassium | Losartan Potassium | 194 | 50 |
| Metoprolol Succinate | Metoprolol Succinate | 179 | 48 |
| Gabapentin | Gabapentin | 166 | 43 |
| Pantoprazole Sodium | Pantoprazole Sodium | 163 | 43 |
| Meloxicam | Meloxicam | 147 | 40 |
| Trazodone Hcl | Trazodone Hcl | 140 | 40 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 120 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 118 | 38 |
| Allopurinol | Allopurinol | 112 | 29 |
| Pravastatin Sodium | Pravastatin Sodium | 106 | 27 |
| Hydrochlorothiazide | Hydrochlorothiazide | 105 | 32 |
| Montelukast Sodium | Montelukast Sodium | 104 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 92 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 85 | 19 |
| Baclofen | Baclofen | 83 | 27 |
| Tamsulosin Hcl | Tamsulosin Hcl | 80 | 23 |
| Ezetimibe | Ezetimibe | 74 | 21 |
| Metformin Hcl Er | Metformin Hcl | 72 | 22 |
| Sertraline Hcl | Sertraline Hcl | 71 | 24 |
| Famotidine | Famotidine | 70 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 70 | 16 |
| Buspirone Hcl | Buspirone Hcl | 69 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 65 | 31 |
| Carvedilol | Carvedilol | 64 | 16 |
| Prednisone | Prednisone | 64 | 49 |
| Fluticasone Propionate | Fluticasone Propionate | 62 | 24 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 62 | 15 |
| Ozempic | Semaglutide | 60 | 14 |
| Fenofibrate | Fenofibrate Nanocrystallized | 57 | 11 |
| Alendronate Sodium | Alendronate Sodium | 56 | 13 |
| Atenolol | Atenolol | 54 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 53 | 17 |
| Spironolactone | Spironolactone | 53 | 15 |
| Cephalexin | Cephalexin | 51 | 37 |
| Tramadol Hcl | Tramadol Hcl | 45 | 16 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 45 | 13 |
| Nystatin | Nystatin | 44 | 22 |
| Alprazolam | Alprazolam | 43 | 13 |
| Eliquis | Apixaban | 43 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 43 | 12 |
| Januvia | Sitagliptin Phosphate | 42 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 42 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 42 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 41 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 40 | 11 |
| Xarelto | Rivaroxaban | 40 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 39 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 39 | 11 |
| Jardiance | Empagliflozin | 39 | 11 |
| Ondansetron Odt | Ondansetron | 38 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 37 | 29 |
| Warfarin Sodium | Warfarin Sodium | 37 | 11 |
| Donepezil Hcl | Donepezil Hcl | 36 | 12 |
| Trulicity | Dulaglutide | 34 | suppressed |
| Synthroid | Levothyroxine Sodium | 33 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 32 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 32 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 32 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 30 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 30 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 28 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 28 | suppressed |
| Ibuprofen | Ibuprofen | 27 | suppressed |
| Chlorthalidone | Chlorthalidone | 26 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Memantine Hcl | Memantine Hcl | 25 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 24 | suppressed |
| Azithromycin | Azithromycin | 23 | 18 |
| Fenofibrate | Fenofibrate | 23 | suppressed |
| Finasteride | Finasteride | 22 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 20 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Pregabalin | Pregabalin | 18 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 17 | suppressed |
| Novolog | Insulin Aspart | 16 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Klor-Con M20 | Potassium Chloride | 15 | suppressed |
| Levofloxacin | Levofloxacin | 15 | 14 |
| Mometasone Furoate | Mometasone Furoate | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 14 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | 11 |
| Colestipol Hcl | Colestipol Hcl | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Unifine Pentips | Pen Needle, Diabetic | 12 | suppressed |
| Cefdinir | Cefdinir | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | 11 |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $278.26 · 13 records | Merck Sharp & Dohme LLC | ABRYSVO, CABOMETYX, CAPVAXIVE, COMIRNATY, Dexcom G6 Transmitter, ENFLONSIA, EVENITY, GARDASIL 9, JAKAFI, KEYTRUDA, KEYTRUDA QLEX, PENBRAYA, PREVNAR 20, PROLIA, TRUMENBA, VOQUEZNA, Wegovy | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error